AI Tokens
Stock Analysis on Net

Becton, Dickinson & Co. (NYSE:BDX)

This company has been moved to the archive! The financial data has not been updated since May 5, 2022.

Common Stock Valuation Ratios (Price Multiples)

Microsoft Excel

Current Valuation Ratios

Becton, Dickinson & Co., current price multiples

Microsoft Excel
Becton, Dickinson & Co. Abbott Laboratories Elevance Health Inc. Intuitive Surgical Inc. Medtronic PLC UnitedHealth Group Inc. Health Care Equipment & Services Health Care
Selected Financial Data
Current share price (P) $259.64
No. shares of common stock outstanding 285,064,629
Growth rate (g) 1.53%
 
Earnings per share (EPS) $7.02
Next year expected EPS $7.13
Operating profit per share $9.82
Sales per share $71.03
Book value per share (BVPS) $83.06
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 36.97 28.17 16.03 52.43 25.72 30.30 25.53 34.25
Price to next year expected earnings 36.41 26.12 14.34 45.97 25.37 26.99 22.97 29.91
Price-earnings-growth (PEG) 24.19 3.59 1.36 3.73 18.77 2.47 2.29 2.36
Price to operating profit (P/OP) 26.44 22.82 13.81 50.84 19.10 19.26 19.96 28.92
Price to sales (P/S) 3.66 4.15 0.46 14.88 3.40 0.82 1.82 5.22
Price to book value (P/BV) 3.13 3.53 2.07 8.40 2.50 3.88 4.41 8.71

Based on: 10-K (reporting date: 2021-09-30).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Becton, Dickinson & Co., historical price multiples

Microsoft Excel
Sep 30, 2021 Sep 30, 2020 Sep 30, 2019 Sep 30, 2018 Sep 30, 2017 Sep 30, 2016
Price to earnings (P/E) 34.68 86.01 65.09 408.36 49.63 36.65
Price to operating profit (P/OP) 24.81 44.46 40.02 43.37 34.59 25.02
Price to sales (P/S) 3.43 3.85 4.07 4.06 4.23 2.87
Price to book value (P/BV) 2.93 2.78 3.34 3.09 3.95 4.69

Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).


The valuation multiples for the period between 2016 and 2021 exhibit significant volatility in earnings-based metrics, while revenue and book value metrics show more stable or gradual transitions. A general trend of valuation expansion occurred between 2017 and 2020, followed by a notable contraction across most ratios in 2021.

Price to Earnings (P/E)
The P/E ratio demonstrates extreme volatility, characterized by a massive spike in 2018 to 408.36. This anomaly suggests a period of severely depressed earnings relative to the stock price. Following this peak, the ratio remained elevated through 2020, reaching 86.01, before correcting sharply in 2021 to 34.68, which is the lowest level recorded in the six-year period.
Price to Operating Profit (P/OP)
A steady increase in the P/OP ratio is observed from 2016 (25.02) through 2020, peaking at 44.46. This indicates that the market was willing to pay a higher premium for operating earnings during this window. Similar to the P/E ratio, a significant correction occurred in 2021, with the ratio falling back to 24.81, returning to near-2016 levels.
Price to Sales (P/S)
The P/S ratio experienced a sharp increase between 2016 (2.87) and 2017 (4.23). For the subsequent three years, the ratio remained relatively stable, fluctuating slightly around the 4.0 mark. A gradual decline began in 2020, ending at 3.43 in 2021, suggesting a cooling of the revenue premium.
Price to Book Value (P/BV)
A consistent downward trend is evident in the P/BV ratio, which declined from a high of 4.69 in 2016 to 2.93 in 2021. This steady contraction indicates a reduction in the market premium applied to the company's net asset value over the observed timeframe.

Overall, the convergence of the P/E, P/OP, and P/S ratios in 2021 suggests a broader valuation realignment. The stark contrast between the 2018 P/E spike and the relative stability of the P/OP and P/S ratios during the same year implies that the 2018 volatility was likely driven by non-operating items affecting net income rather than a fundamental shift in operational performance or market sentiment.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Earnings (P/E)

Becton, Dickinson & Co., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Sep 30, 2021 Sep 30, 2020 Sep 30, 2019 Sep 30, 2018 Sep 30, 2017 Sep 30, 2016
No. shares of common stock outstanding1 284,023,582 290,031,363 270,459,892 268,257,940 227,978,328 212,319,588
Selected Financial Data (US$)
Net income applicable to common shareholders (in millions) 2,002 767 1,082 159 1,030 976
Earnings per share (EPS)2 7.05 2.64 4.00 0.59 4.52 4.60
Share price1, 3 244.46 227.47 260.40 242.04 224.23 168.48
Valuation Ratio
P/E ratio4 34.68 86.01 65.09 408.36 49.63 36.65
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 29.13 — — — — —
Elevance Health Inc. 18.13 — — — — —
Intuitive Surgical Inc. 59.94 — — — — —
Medtronic PLC 46.56 — — — — —
UnitedHealth Group Inc. 26.03 — — — — —
P/E Ratio, Sector
Health Care Equipment & Services 28.98 — — — — —
P/E Ratio, Industry
Health Care 21.55 — — — — —

Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
EPS = Net income applicable to common shareholders ÷ No. shares of common stock outstanding
= 2,002,000,000 ÷ 284,023,582 = 7.05

3 Closing price as at the filing date of Becton, Dickinson & Co. Annual Report.

4 2021 Calculation
P/E ratio = Share price ÷ EPS
= 244.46 ÷ 7.05 = 34.68

5 Click competitor name to see calculations.


The valuation metrics from 2016 to 2021 exhibit significant volatility, characterized by a decoupling of share price movements and earnings per share (EPS). While the share price followed a generally ascending trajectory for the majority of the period, the P/E ratio fluctuated drastically due to instability in bottom-line earnings.

Price to Earnings (P/E) Ratio Analysis
The P/E ratio experienced extreme variance, peaking in 2018 at 408.36. This outlier was not the result of a proportional surge in share price, but rather a sharp contraction in EPS. Following this peak, the ratio trended downward toward 65.09 in 2019, rose again to 86.01 in 2020, and ultimately reached its period low of 34.68 in 2021. This final decline indicates a significant compression of the valuation multiple as earnings recovered.
Earnings per Share (EPS) Performance
Earnings demonstrated a non-linear and volatile pattern. After remaining stable at approximately $4.50 through 2017, EPS plummeted to $0.59 in 2018. A recovery to $4.00 occurred in 2019, followed by a dip to $2.64 in 2020. The period concluded with a substantial increase to $7.05 in 2021, representing the highest earnings level in the observed timeframe.
Share Price Trends
The share price showed consistent growth from $168.48 in 2016 to a peak of $260.40 in 2019. Despite a moderate correction to $227.47 in 2020, the price recovered to $244.46 by 2021. The relative stability of the share price during the 2018 earnings collapse suggests that market sentiment remained decoupled from short-term earnings volatility.

Overall, the data indicates that the volatility in the P/E ratio was primarily driven by fluctuations in EPS rather than speculative swings in the share price. The convergence of a stabilized share price and record-high EPS in 2021 resulted in a more conservative valuation multiple compared to the preceding five years.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Operating Profit (P/OP)

Becton, Dickinson & Co., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Sep 30, 2021 Sep 30, 2020 Sep 30, 2019 Sep 30, 2018 Sep 30, 2017 Sep 30, 2016
No. shares of common stock outstanding1 284,023,582 290,031,363 270,459,892 268,257,940 227,978,328 212,319,588
Selected Financial Data (US$)
Operating income (in millions) 2,799 1,484 1,760 1,497 1,478 1,430
Operating profit per share2 9.85 5.12 6.51 5.58 6.48 6.74
Share price1, 3 244.46 227.47 260.40 242.04 224.23 168.48
Valuation Ratio
P/OP ratio4 24.81 44.46 40.02 43.37 34.59 25.02
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 24.45 — — — — —
Elevance Health Inc. 15.70 — — — — —
Intuitive Surgical Inc. 56.11 — — — — —
Medtronic PLC 37.44 — — — — —
UnitedHealth Group Inc. 18.77 — — — — —
P/OP Ratio, Sector
Health Care Equipment & Services 22.66 — — — — —
P/OP Ratio, Industry
Health Care 18.20 — — — — —

Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 2,799,000,000 ÷ 284,023,582 = 9.85

3 Closing price as at the filing date of Becton, Dickinson & Co. Annual Report.

4 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 244.46 ÷ 9.85 = 24.81

5 Click competitor name to see calculations.


The valuation of common stock relative to operating profit exhibited a period of significant expansion followed by a sharp contraction between 2016 and 2021. The relationship between share price and operational earnings suggests a shift in valuation multiples over this six-year horizon.

P/OP Ratio Expansion (2016–2020)
A consistent upward trend in the P/OP ratio is observed from 2016 to 2020, rising from 25.02 to a peak of 44.46. This expansion indicates that the share price increased at a pace that significantly outstripped the growth of operating profits per share during this interval.
Operating Profit Volatility
Operating profit per share demonstrated a general downward trend and instability between 2016 and 2020, declining from 6.74 to a low of 5.12. This erosion of per-share operating profitability acted as a primary driver for the increasing P/OP multiple, as the market maintained higher share prices despite diminishing operating returns.
Valuation Realignment (2021)
A substantial correction in the valuation multiple occurred in 2021, with the P/OP ratio dropping sharply to 24.81. This compression was precipitated by a significant surge in operating profit per share, which rose to 9.85. The increase in profitability far exceeded the modest recovery in share price, effectively returning the valuation multiple to levels observed in 2016.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Sales (P/S)

Becton, Dickinson & Co., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Sep 30, 2021 Sep 30, 2020 Sep 30, 2019 Sep 30, 2018 Sep 30, 2017 Sep 30, 2016
No. shares of common stock outstanding1 284,023,582 290,031,363 270,459,892 268,257,940 227,978,328 212,319,588
Selected Financial Data (US$)
Revenues (in millions) 20,248 17,117 17,290 15,983 12,093 12,483
Sales per share2 71.29 59.02 63.93 59.58 53.04 58.79
Share price1, 3 244.46 227.47 260.40 242.04 224.23 168.48
Valuation Ratio
P/S ratio4 3.43 3.85 4.07 4.06 4.23 2.87
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.78 — — — — —
Elevance Health Inc. 0.81 — — — — —
Intuitive Surgical Inc. 17.89 — — — — —
Medtronic PLC 5.57 — — — — —
UnitedHealth Group Inc. 1.58 — — — — —
P/S Ratio, Sector
Health Care Equipment & Services 2.07 — — — — —
P/S Ratio, Industry
Health Care 3.28 — — — — —

Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= 20,248,000,000 ÷ 284,023,582 = 71.29

3 Closing price as at the filing date of Becton, Dickinson & Co. Annual Report.

4 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 244.46 ÷ 71.29 = 3.43

5 Click competitor name to see calculations.


The valuation of the company based on the Price-to-Sales (P/S) ratio exhibited a significant initial expansion followed by a period of gradual contraction between 2016 and 2021. The ratio increased sharply from 2.87 in 2016 to a peak of 4.23 in 2017, after which it trended downward to 3.43 by the end of the period.

Initial Valuation Surge (2016-2017)
A substantial increase in the P/S ratio is observed between 2016 and 2017. This expansion was primarily driven by a marked increase in the share price, which rose from US$ 168.48 to US$ 224.23, while sales per share concurrently decreased from US$ 58.79 to US$ 53.04. This divergence indicates that market valuation increased independently of top-line revenue performance during this interval.
Period of Valuation Stability (2018-2019)
The P/S ratio remained relatively stable during 2018 and 2019, fluctuating minimally between 4.06 and 4.07. During this phase, the growth in share price was largely mirrored by a corresponding increase in sales per share, maintaining a consistent valuation multiple.
Recent Valuation Compression (2020-2021)
A downward trend in the P/S ratio occurred from 2020 to 2021, reaching 3.43. Although the share price recovered from a dip in 2020 to reach US$ 244.46 in 2021, the growth in sales per share was more pronounced, peaking at US$ 71.29. The acceleration in revenue per share relative to the share price growth resulted in a compression of the price multiple.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Book Value (P/BV)

Becton, Dickinson & Co., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Sep 30, 2021 Sep 30, 2020 Sep 30, 2019 Sep 30, 2018 Sep 30, 2017 Sep 30, 2016
No. shares of common stock outstanding1 284,023,582 290,031,363 270,459,892 268,257,940 227,978,328 212,319,588
Selected Financial Data (US$)
Shareholders’ equity (in millions) 23,677 23,765 21,081 20,994 12,948 7,633
Book value per share (BVPS)2 83.36 81.94 77.95 78.26 56.79 35.95
Share price1, 3 244.46 227.47 260.40 242.04 224.23 168.48
Valuation Ratio
P/BV ratio4 2.93 2.78 3.34 3.09 3.95 4.69
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.75 — — — — —
Elevance Health Inc. 3.07 — — — — —
Intuitive Surgical Inc. 8.59 — — — — —
Medtronic PLC 3.26 — — — — —
UnitedHealth Group Inc. 6.27 — — — — —
P/BV Ratio, Sector
Health Care Equipment & Services 5.01 — — — — —
P/BV Ratio, Industry
Health Care 5.48 — — — — —

Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
BVPS = Shareholders’ equity ÷ No. shares of common stock outstanding
= 23,677,000,000 ÷ 284,023,582 = 83.36

3 Closing price as at the filing date of Becton, Dickinson & Co. Annual Report.

4 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 244.46 ÷ 83.36 = 2.93

5 Click competitor name to see calculations.


The financial data from 2016 to 2021 indicates a notable compression in the valuation multiple relative to the company's book value. While both the market price and the intrinsic book value increased over the six-year period, the rate of growth in the book value per share significantly exceeded the rate of share price appreciation.

Share Price Performance
The share price trended upward from 168.48 US$ in 2016 to a high of 260.40 US$ in 2019, followed by a period of volatility that resulted in a closing price of 244.46 US$ in 2021.
Book Value per Share (BVPS) Trajectory
A consistent and substantial increase in BVPS is observed, rising from 35.95 US$ in 2016 to 83.36 US$ in 2021. The most aggressive growth occurred between 2016 and 2018, where the value more than doubled, indicating a strong increase in the net asset value attributable to each share.
Price to Book Value (P/BV) Analysis
The P/BV ratio experienced a steady decline from 4.69 in 2016 to 2.93 in 2021. This downward trend demonstrates that the market's valuation of the company's equity became more conservative relative to its accounting book value over time. The compression of the multiple is a direct result of BVPS growing at a faster pace than the share price.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?